Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis
Year: 2023
Type: article
Abstract: ■ AD is a chronic skin disease that can be a serious burden, affecting sleep, daily activities, and social relationships 1 ■ Lebrikizumab is a monoclonal antibody that binds with high affinity and slow off-rate to IL-13, thereby blocking the downstream effects of IL-13 with high potency 2 ■ Integrated safety data for lebrikizumab treatment in moderate-to-severe AD has been previously published in Phase 2 and 3 clinical trials 3-6 ■ Conjunctivitis and keratitis are events of special interest in moderate-to-severe AD and are reported more frequently in lebrikizumab-treated patients 7 OBJECTIVE ■ To further characterize patient-reported conjunctivitis and keratitis AEs in patients with moderate-to-severe AD participating in lebrikizumab clinical trials for AD KEY RESULTS Incidence Rate of Conjunctivitis and Keratitis Clusters Did Not Increase With Longer Duration of Exposure CONCLUSIONS■ The majority of conjunctivitis and keratitis cluster events reported by lebrikizumabtreated patients were mild or moderate in severity, did not lead to treatment discontinuation, and were resolved or resolving at the time of the database lock ■ The majority of conjunctivitis cluster events were reported during the first 16 weeks of treatment ■ Incidence rate of conjunctivitis and keratitis cluster events did not increase with longer duration of exposure ■ Patients with medical history of conjunctivitis may have higher risk of developing treatment-emergent conjunctivitis or keratitis
Institutions: University of California, Los Angeles, University Hospital Augsburg, Ludwig-Maximilians-Universität München, University Medical Center Utrecht, Northwestern University, Eli Lilly (United States), Almirall (Spain), National Taiwan University, National Taiwan University Hospital, Aarhus University
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4388627423